Creative Planning Rigel Pharmaceuticals Inc Transaction History

Creative Planning

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 16, 2023	BUY	$1.07 - $1.39 $12,575 - $16,336	11,753 New	11,753 $12,000
Q4 2021 Feb 11, 2022	SELL	$2.36 - $3.57 $23,600 - $35,700	-10,000 Closed	0 $0
Q2 2021 Aug 04, 2021	SELL	$3.09 - $4.54 $31,518 - $46,308	-10,200 Reduced 50.5%	10,000 $43,000
Q1 2021 Apr 30, 2021	BUY	$3.35 - $4.93 $33,500 - $49,300	10,000 Added 98.04%	20,200 $69,000
Q4 2020 Jan 29, 2021	SELL	$2.35 - $3.74 $23,500 - $37,400	-10,000 Reduced 49.5%	10,200 $36,000
Q2 2020 Jul 23, 2020	BUY	$1.41 - $2.05 $282 - $409	200 Added 1.0%	20,200 $37,000
Q3 2018 Oct 25, 2018	BUY	$2.6 - $3.59 $26,000 - $35,900	10,000 Added 100.0%	20,000 $64,000
Q1 2018 Apr 18, 2018	SELL	$3.54 - $4.54 $3,540 - $4,540	-1,000 Reduced 9.09%	10,000 $35,000
Q4 2017 Jan 17, 2018	BUY	$3.23 - $4.3 $3,230 - $4,300	1,000 Added 10.0%	11,000 $43,000
Q3 2017 Oct 17, 2017	BUY	$2.18 - $2.57 $21,800 - $25,700	10,000	10,000 $25,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.